Sanofi/$SNY
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Sanofi
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
Ticker
$SNY
Sector
Primary listing
Employees
82,878
Headquarters
Website
Sanofi Metrics
BasicAdvanced
$114B
5.42
$8.66
0.44
$1.60
3.40%
Price and volume
Market cap
$114B
Beta
0.44
52-week high
$60.12
52-week low
$44.73
Average daily volume
2.7M
Dividend rate
$1.60
Financial strength
Current ratio
1.274
Quick ratio
0.542
Long term debt to equity
20.951
Total debt to equity
31.709
Dividend payout ratio (TTM)
52.29%
Interest coverage (TTM)
16.91%
Profitability
EBITDA (TTM)
14,248.423
Gross margin (TTM)
71.34%
Net profit margin (TTM)
19.95%
Operating margin (TTM)
20.51%
Effective tax rate (TTM)
19.24%
Revenue per employee (TTM)
$648,620
Management effectiveness
Return on assets (TTM)
4.60%
Return on equity (TTM)
9.00%
Valuation
Price to earnings (TTM)
5.424
Price to revenue (TTM)
1.079
Price to book
1.38
Price to tangible book (TTM)
5.58
Price to free cash flow (TTM)
5.875
Free cash flow yield (TTM)
17.02%
Free cash flow per share (TTM)
7.995
Dividend yield (TTM)
3.40%
Forward dividend yield
3.40%
Growth
Revenue change (TTM)
15.65%
Earnings per share change (TTM)
118.56%
3-year revenue growth (CAGR)
2.85%
10-year revenue growth (CAGR)
3.35%
3-year earnings per share growth (CAGR)
11.66%
10-year earnings per share growth (CAGR)
7.20%
3-year dividend per share growth (CAGR)
5.59%
10-year dividend per share growth (CAGR)
3.24%
What the Analysts think about Sanofi
Analyst ratings (Buy, Hold, Sell) for Sanofi stock.
Bulls say / Bears say
Dupixent sales rose 21.1% to €3.83 billion in Q2, prompting Sanofi to raise its full-year sales growth forecast to high single digits. (Reuters)
The FDA approved Wayrilz (rilzabrutinib) for chronic immune thrombocytopenia in August, marking a successful integration of the Principia Biopharma acquisition and analysts forecast peak sales of $2–5 billion. (Reuters)
Dupixent generated over €1 billion in sales outside the U.S. in Q2 despite price reductions in China, demonstrating resilient international demand. (Reuters)
Quarterly business operating income excluding one-offs grew only 3.3% despite 21.1% sales growth, weighed down by higher R&D spending and profit-sharing with Regeneron. (Reuters)
Sanofi’s reliance on Dupixent, expected to account for over a third of revenue this year, heightens concentration risk if growth slows or biosimilars emerge. (Reuters Breakingviews)
Sanofi’s $9.5 billion acquisition of Blueprint Medicines to reduce Dupixent dependency may strain returns given Blueprint’s current operating losses and competitive threats. (Reuters Breakingviews)
Data summarised monthly by Lightyear AI. Last updated on 3 Sept 2025.
Sanofi Financial Performance
Revenues and expenses
Sanofi Earnings Performance
Company profitability
Sanofi News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Sanofi stock?
Sanofi (SNY) has a market cap of $114B as of September 18, 2025.
What is the P/E ratio for Sanofi stock?
The price to earnings (P/E) ratio for Sanofi (SNY) stock is 5.42 as of September 18, 2025.
Does Sanofi stock pay dividends?
Yes, the Sanofi (SNY) stock pays dividends to shareholders. As of September 18, 2025, the dividend rate is $1.59864 and the yield is 3.4%. Sanofi has a payout ratio of 52.29% on a trailing twelve-month basis.
When is the next Sanofi dividend payment date?
The next Sanofi (SNY) dividend payment date is unconfirmed.
What is the beta indicator for Sanofi?
Sanofi (SNY) has a beta rating of 0.44. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.